We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell t... Carisma Therapeutics Inc. is a clinical-stage cell therapy company. The Company is focused on utilizing the Company¿s macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The Company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells. The Company¿s lead product candidate, CT-0508, is a Chimeric Antigen Receptor Macrophage (CAR-M) to be evaluated in a human clinical trial and is intended to treat solid tumors that overexpress HER2. The Company¿s second product candidate, CT-0525, is also intended to treat solid tumors that overexpress HER2, is in preclinical development. Beyond CT-0508 and CT-0525, the Company has a pipeline of cell therapy assets in various stages of pre-clinical development. The Company is also developing in vivo CAR-M gene therapies. Show more
Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire PHILADELPHIA, April 24, 2024 PHILADELPHIA, April 24, 2024...
Regulatory News: Carmila (Paris:CARM) has signed a cash share buyback mandate with an investment service provider for a maximum amount of €10 million. The purchase period will start on 29 April...
Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting PR Newswire PHILADELPHIA, April 22, 2024 Preclinical data highlights the potential...
Net rental income up +4.0% like-for-like versus first quarter 2023 Excellent commercial momentum: 210 leases signed in the first quarter (+19%), positive reversion (+3.4%) Financial occupancy at...
Regulatory News: Carmila (Paris:CARM) : Date Nombre d’actions composant le capital social Nombre réel de droits de vote (déduction faite des actions auto-détenues) Nombre théorique de droits de...
Carisma Therapeutics to Present at Upcoming Conferences PR Newswire PHILADELPHIA, April 3, 2024 PHILADELPHIA, April 3, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or...
Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire PHILADELPHIA, April 1, 2024 Company to prioritize CT-0525 as its...
Carisma Therapeutics Announces Changes to its Board of Directors PR Newswire PHILADELPHIA, April 1, 2024 Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA, April 1...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -4.11764705882 | 1.7 | 1.91 | 1.53 | 139972 | 1.69822523 | CS |
| 4 | -0.64 | -28.1938325991 | 2.27 | 2.3 | 1.53 | 196329 | 1.86729291 | CS |
| 12 | -0.57 | -25.9090909091 | 2.2 | 2.77 | 1.53 | 171904 | 2.19077315 | CS |
| 26 | -1.14 | -41.155234657 | 2.77 | 3.4179 | 1.53 | 171003 | 2.44360348 | CS |
| 52 | -2.36 | -59.1478696742 | 3.99 | 9.7662 | 1.53 | 223746 | 4.81323583 | CS |
| 156 | -4.16 | -71.8480138169 | 5.79 | 9.7662 | 1.53 | 217793 | 4.68954272 | CS |
| 260 | -4.16 | -71.8480138169 | 5.79 | 9.7662 | 1.53 | 217793 | 4.68954272 | CS |
PonkenPlonken
1 week ago
Monksdream
4 weeks ago
mrplmer
4 months ago
mrplmer
4 months ago
81vette
4 months ago
81vette
4 months ago
stock1ace1
4 months ago
81vette
4 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
